Fortress Biotech to Host Virtual Annual Meeting of Stockholders

NEXT STORY
Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
PREV STORY
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease

author_avatar
NASDAQ Market News

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

author_avatar
NASDAQ Market News

CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer

author_avatar
NASDAQ Market News